Tesamorelin Research Compound
Research Use Only
This product is intended for laboratory research purposes only. It is not intended for human or veterinary use, food, cosmetic, household, or agricultural applications. Not for human consumption.
Overview
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that has received FDA approval (Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. This clinical validation provides a well-characterized safety and efficacy profile for research applications.
Mechanism of Action
Tesamorelin stimulates GH release through GHRH receptor activation:
- Modified GHRH (1-44) with trans-3-hexenoic acid
- Enhanced stability vs. native GHRH
- Pulsatile GH release stimulation
- Maintained physiological feedback mechanisms
Clinical Background
| Status | Details |
|---|---|
| FDA Approval | 2010 (Egrifta) |
| Indication | HIV-associated lipodystrophy |
| Mechanism | GHRH receptor agonist |
Research Applications
- Clinical-grade GHRH research
- Lipodystrophy models
- Body composition studies
- Long-term GH secretagogue research
Handling & Storage
- Store lyophilized peptide at -20C
- Protect from light and moisture
- Reconstitute with bacteriostatic water
- Reconstituted solution stable at 2-8C for up to 4 weeks